S&P 500   5,199.06
DOW   38,459.08
QQQ   445.37
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024
Stock market today: Global markets mixed after Wall St rebound led by Big Tech
3 High-Yield Stocks In Rebound Mode: How High Can They Go?
Dividend Aristocrat Fastenal Goes on Sale: Buy It While It’s Down
NVIDIA Enters Correction: Worry or Opportunity?
How major US stock indexes fared Thursday, 4/11/2024
Blackstone’s $10 Billion Bet on Property Prices Going Up
S&P 500   5,199.06
DOW   38,459.08
QQQ   445.37
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024
Stock market today: Global markets mixed after Wall St rebound led by Big Tech
3 High-Yield Stocks In Rebound Mode: How High Can They Go?
Dividend Aristocrat Fastenal Goes on Sale: Buy It While It’s Down
NVIDIA Enters Correction: Worry or Opportunity?
How major US stock indexes fared Thursday, 4/11/2024
Blackstone’s $10 Billion Bet on Property Prices Going Up
S&P 500   5,199.06
DOW   38,459.08
QQQ   445.37
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024
Stock market today: Global markets mixed after Wall St rebound led by Big Tech
3 High-Yield Stocks In Rebound Mode: How High Can They Go?
Dividend Aristocrat Fastenal Goes on Sale: Buy It While It’s Down
NVIDIA Enters Correction: Worry or Opportunity?
How major US stock indexes fared Thursday, 4/11/2024
Blackstone’s $10 Billion Bet on Property Prices Going Up
S&P 500   5,199.06
DOW   38,459.08
QQQ   445.37
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024
Stock market today: Global markets mixed after Wall St rebound led by Big Tech
3 High-Yield Stocks In Rebound Mode: How High Can They Go?
Dividend Aristocrat Fastenal Goes on Sale: Buy It While It’s Down
NVIDIA Enters Correction: Worry or Opportunity?
How major US stock indexes fared Thursday, 4/11/2024
Blackstone’s $10 Billion Bet on Property Prices Going Up

Merus (MRUS) Stock Price, News & Analysis

$43.09
+1.35 (+3.23%)
(As of 04/11/2024 ET)
Today's Range
$41.98
$43.19
50-Day Range
$35.46
$51.82
52-Week Range
$18.21
$52.03
Volume
558,801 shs
Average Volume
509,079 shs
Market Capitalization
$2.49 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$53.64

Merus MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
24.5% Upside
$53.64 Price Target
Short Interest
Healthy
5.94% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.18mentions of Merus in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($3.29) to ($3.46) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.61 out of 5 stars

Medical Sector

2098th out of 2,796 stocks

Biotechnology Industry

121st out of 165 stocks

MRUS stock logo

About Merus Stock (NASDAQ:MRUS)

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

MRUS Stock Price History

MRUS Stock News Headlines

Gold Hits New All-Time Highs
Due to both domestic and global issues, the trajectory of this precious metal could skyrocket in the coming months… Which is why billionaires and Central Banks alike are scooping up gold at record rates!
MRUS Dec 2024 50.000 call
MRUS Jan 2025 50.000 put
MRUS Apr 2024 35.000 put
Gold Hits New All-Time Highs
Due to both domestic and global issues, the trajectory of this precious metal could skyrocket in the coming months… Which is why billionaires and Central Banks alike are scooping up gold at record rates!
MRUS Apr 2024 40.000 call
Merus Full Year 2023 Earnings: Misses Expectations
MRUS Apr 2024 40.000 put
Stifel Nicolaus Keeps Their Buy Rating on Merus (MRUS)
MRUS Mar 2024 40.000 call
MRUS Sep 2024 55.000 call
See More Headlines
Receive MRUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merus and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
4/11/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:MRUS
Fax
N/A
Employees
172
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$53.64
High Stock Price Target
$69.00
Low Stock Price Target
$35.00
Potential Upside/Downside
+24.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
12 Analysts

Profitability

Net Income
$-154,940,000.00
Net Margins
-352.56%
Pretax Margin
-345.30%

Debt

Sales & Book Value

Annual Sales
$43.95 million
Book Value
$6.17 per share

Miscellaneous

Free Float
55,389,000
Market Cap
$2.49 billion
Optionable
Optionable
Beta
1.10
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Sven Ante Lundberg M.D. (Age 61)
    CEO, President & Executive Director
    Comp: $953.06k
  • Mr. Gregory D. Perry (Age 64)
    Chief Financial Officer
    Comp: $63.76k
  • Mr. Peter B. Silverman J.D. (Age 46)
    EVP, Company Secretary, COO, General Counsel, Chief Intellectual Property Officer & Head of US Legal
    Comp: $601.19k
  • Dr. Hui Liu Ph.D. (Age 57)
    Chief Business Officer, Executive VP & Head of Merus U.S.
    Comp: $597.7k
  • Dr. Andrew Joe M.D. (Age 57)
    Chief Medical Officer & Senior VP
    Comp: $692.74k
  • Dr. Hennie Hoogenboom
    Co-Founder and Scientific Advisor
  • Harry Shuman
    Chief Accounting Officer
  • Mr. Cornelis Adriaan de Kruif Ph.D. (Age 59)
    CTO & Executive VP
    Comp: $350.85k
  • Dr. Cecilia Anna Wilhelmina Geuijen Ph.D.
    Chief Scientific Officer & Senior VP
  • Kathleen Farren
    IR & Corporate Communications Officer

MRUS Stock Analysis - Frequently Asked Questions

Should I buy or sell Merus stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merus in the last year. There are currently 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MRUS shares.
View MRUS analyst ratings
or view top-rated stocks.

What is Merus' stock price target for 2024?

12 equities research analysts have issued 1-year target prices for Merus' shares. Their MRUS share price targets range from $35.00 to $69.00. On average, they predict the company's share price to reach $53.64 in the next twelve months. This suggests a possible upside of 24.5% from the stock's current price.
View analysts price targets for MRUS
or view top-rated stocks among Wall Street analysts.

How have MRUS shares performed in 2024?

Merus' stock was trading at $27.50 at the beginning of the year. Since then, MRUS stock has increased by 56.7% and is now trading at $43.09.
View the best growth stocks for 2024 here
.

When is Merus' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our MRUS earnings forecast
.

How were Merus' earnings last quarter?

Merus (NASDAQ:MRUS) released its earnings results on Wednesday, February, 28th. The biotechnology company reported ($1.09) EPS for the quarter, missing analysts' consensus estimates of ($0.71) by $0.38. The biotechnology company earned $8.94 million during the quarter, compared to the consensus estimate of $10.43 million. Merus had a negative trailing twelve-month return on equity of 50.61% and a negative net margin of 352.56%.

What ETFs hold Merus' stock?
What other stocks do shareholders of Merus own?
When did Merus IPO?

Merus (MRUS) raised $64 million in an IPO on Thursday, May 19th 2016. The company issued 4,300,000 shares at $14.00-$16.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.

How do I buy shares of Merus?

Shares of MRUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MRUS) was last updated on 4/12/2024 by MarketBeat.com Staff

From Our Partners